Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2021-10-14 Capital/Financing Update
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx Solutions AS: Styrker likviditeten
Capital/Financing Update Classification · 98% confidence The document announces that the Board of Directors of SoftOx Solutions AS has entered into a loan agreement with a major shareholder to inject NOK 15 million in short-term liquidity to compensate for delays in regulatory processes and clinical studies. The terms include a 12-month, non-interest-bearing loan with an option for the lender to convert the loan into equity at a discount to the recent volume-weighted average price. This transaction directly relates to the company's financing activities and capital structure adjustments. This fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific financing event.
2021-10-14 Norwegian
SOFTOX SOLUTIONS: APPROVAL RECEIVED FROM DANISH MEDICINES AGENCY TO COMMENCE FIRST CLINICAL TRIAL OF SOFTOX INHALED SOLUTION (SIS)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 6, 2021, announcing that SoftOx Solutions received approval from the Danish Medicines Agency (DKMA) to commence Phase 1 clinical trials for its product, SoftOx Inhaled Solution (SIS). It details the nature of the trial (safety and tolerability), the intended use (respiratory tract infections, including COVID-19), and includes quotes from management. This type of announcement, detailing regulatory milestones and clinical trial initiation, is a general corporate update. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a specific financial filing like a Dividend Notice (DIV) or Director's Dealing (DIRS). Since it is a significant, non-financial regulatory/development update that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The document length (3403 chars) is short, but it is the primary announcement itself, not an announcement *about* another report, so RPA is less suitable than RNS for this type of clinical/regulatory news.
2021-10-06 English
SOFTOX SOLUTIONS: HAR FÅTT GODKJENNING FRA DANSKE LÆGEMIDDELSTYRELSEN FOR Å STARTE FØRSTE KLINISKE STUDI AV SOFTOX INNHALASJONS LØSNING (SIS)
Regulatory Filings Classification · 97% confidence The document is a press release from SoftOx Solutions AS, dated October 6, 2021, announcing that the Danish Medicines Agency (Danske Lægemiddelstyrelsen) has approved Phase 1 clinical trials for their inhalation solution (SIS). The text details the nature of the study (Phase 1, safety, tolerance), the target indication (respiratory infections, starting with SARS-CoV-2), and includes quotes from management. This type of announcement, detailing regulatory milestones and clinical trial initiation for a drug candidate, is typically classified as a general regulatory announcement or a specific update related to product development. Since there is no specific code for 'Clinical Trial Approval Announcement' and it is not a full financial report (10-K, IR), nor a management change (MANG), nor a dividend notice (DIV), it fits best under the general 'Regulatory Filings' (RNS) category, as it is an official public disclosure of a significant regulatory event. Given the short length (3376 chars) and the nature of the announcement (a press release about regulatory progress), RNS is the most appropriate general classification.
2021-10-06 Norwegian
SoftOx Solutions AS has received a response from the Ministry of Climate and Environment
Legal Proceedings Report Classification · 100% confidence The document is a short update from SoftOx Solutions AS regarding a regulatory decision from the Ministry of Climate and Environment concerning the approval of biocidal products in Norway. It details the status of an application and the resulting temporary suspension of sales, referencing a previous stock exchange announcement. This type of communication, which addresses a specific legal/regulatory matter impacting operations (a decision on product approval), fits best under the 'Legal Proceedings Report' (LTR) category, as it concerns regulatory action/rejection impacting the business, or potentially 'Regulatory Filings' (RNS) as a general regulatory update. Given the specific nature of the regulatory setback and its direct impact, LTR is a strong candidate, but since it's an update on an application process rather than a formal lawsuit or enforcement action, RNS (General regulatory announcements/fallback) is often used for these types of administrative updates that don't fit the other specific categories like ER, 10-K, or DIV. However, since it directly concerns a regulatory decision impacting product market access, and it is not a standard financial report, RNS is the most appropriate general regulatory category here, as LTR usually implies litigation or formal enforcement. Given the context of regulatory interaction, RNS is the safest classification for a non-financial, non-meeting related regulatory status update.
2021-09-30 English
SoftOx Solutions AS har mottatt svar fra Klima- og miljødepartementet
Legal Proceedings Report Classification · 100% confidence The document is a short announcement (1468 characters) from SoftOx Solutions AS regarding a decision from the Ministry of Climate and Environment concerning the national approval of biocidal products (disinfectants). It details the rejection of an appeal and the temporary suspension of sales pending a decision from Sweden. The text explicitly states that the information is defined as inside information according to MAR Article 7 and is being publicly disclosed. Since this is a specific, material announcement that doesn't fit the definitions for 10-K, ER, IR, or DIV, and it is a regulatory disclosure of a significant event, it best fits the general 'Regulatory Filings' category (RNS) as a fallback for material, non-standard announcements, or potentially LTR if it were a legal proceeding, but this is a regulatory administrative decision. Given the nature of a specific, material update that doesn't fit the other specific categories, RNS is the most appropriate general regulatory disclosure code.
2021-09-30 Norwegian
SoftOx Solutions AS har mottatt svar fra Klima- og miljødepartementet
Legal Proceedings Report Classification · 100% confidence The document is a short announcement (2968 characters) from SoftOx Solutions AS regarding receiving a negative response from the Norwegian Ministry of Climate and Environment concerning the temporary suspension of a sales ban on their disinfectant products. It discusses ongoing regulatory/legal processes in Norway and Sweden (KemI, Mark- och Miljödomstolar) and mentions previous stock exchange announcements. Since this is a brief update about a regulatory/legal matter and the status of a product approval process, and it is not a full financial report (10-K, IR) or a formal proxy/dividend notice, it fits best as a general Regulatory Filing (RNS) or potentially a Legal Proceedings Report (LTR) if the focus was purely on the lawsuit. Given the context of updating the market on a regulatory decision affecting operations, RNS is the most appropriate general category for non-standard regulatory news updates, especially since it references prior stock exchange announcements.
2021-09-22 Norwegian

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.